APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitors

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Selected research

Industry Research

PD-1 and PD-L1 Inhibitors Industry Research Report 2026

29 December 2025125 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitors Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

Report Scope

Read the full market overview

This report quantifies the global PD-1 and PD-L1 Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

PD-1 and PD-L1 Inhibitors Market by Company

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors

Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of PD-1 and PD-L1 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of PD-1 and PD-L1 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global PD-1 and PD-L1 Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global PD-1 and PD-L1 Inhibitors Sales (L) of Manufacturers (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global PD-1 and PD-L1 Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market PD-1 and PD-L1 Inhibitors Average Price (USD/ml) of Manufacturers (2021-2026) Table 11. Global PD-1 and PD-L1 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of PD-1 and PD-L1 Inhibitors, Product Type & Application Table 14. Global PD-1 and PD-L1 Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global PD-1 and PD-L1 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Merck Company Information Table 19. Merck Business Overview Table 20. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 21. Merck PD-1 and PD-L1 Inhibitors Product Portfolio Table 22. Merck Recent Developments Table 23. Bristol-Myers Squibb Company Information Table 24. Bristol-Myers Squibb Business Overview Table 25. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 26. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio Table 27. Bristol-Myers Squibb Recent Developments Table 28. Roche Company Information Table 29. Roche Business Overview Table 30. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 31. Roche PD-1 and PD-L1 Inhibitors Product Portfolio Table 32. Roche Recent Developments Table 33. AstraZeneca Company Information Table 34. AstraZeneca Business Overview Table 35. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 36. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio Table 37. AstraZeneca Recent Developments Table 38. Ono Pharmaceutical Company Information Table 39. Ono Pharmaceutical Business Overview Table 40. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 41. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio Table 42. Ono Pharmaceutical Recent Developments Table 43. Regeneron Company Information Table 44. Regeneron Business Overview Table 45. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 46. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio Table 47. Regeneron Recent Developments Table 48. Innovent Company Information Table 49. Innovent Business Overview Table 50. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 51. Innovent PD-1 and PD-L1 Inhibitors Product Portfolio Table 52. Innovent Recent Developments Table 53. Hengrui Medicine Company Information Table 54. Hengrui Medicine Business Overview Table 55. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 56. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio Table 57. Hengrui Medicine Recent Developments Table 58. Junshi Biosciences Company Information Table 59. Junshi Biosciences Business Overview Table 60. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 61. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio Table 62. Junshi Biosciences Recent Developments Table 63. Merck KGaA Company Information Table 64. Merck KGaA Business Overview Table 65. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 66. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio Table 67. Merck KGaA Recent Developments Table 68. Global PD-1 and PD-L1 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026) & (L) Table 70. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2026) Table 71. Global PD-1 and PD-L1 Inhibitors Sales by Region (2027-2032) & (L) Table 72. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2027-2032) Table 73. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 74. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2026) Table 75. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 76. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2027-2032) Table 77. North America PD-1 and PD-L1 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 79. North America PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 80. North America PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 81. North America PD-1 and PD-L1 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe PD-1 and PD-L1 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 84. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 85. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 89. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 90. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 92. South America PD-1 and PD-L1 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 94. South America PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 95. South America PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 96. South America PD-1 and PD-L1 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 99. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 100. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 102. Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 103. Global PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 104. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2026) Table 105. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2027-2032) Table 106. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 107. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 108. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2026) Table 109. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2027-2032) Table 110. Global PD-1 and PD-L1 Inhibitors Price by Type (2021-2026) & (USD/ml) Table 111. Global PD-1 and PD-L1 Inhibitors Price by Type (2027-2032) & (USD/ml) Table 112. Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 113. Global PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 114. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2026) Table 115. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2027-2032) Table 116. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 117. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 118. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2026) Table 119. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2027-2032) Table 120. Global PD-1 and PD-L1 Inhibitors Price by Application (2021-2026) & (USD/ml) Table 121. Global PD-1 and PD-L1 Inhibitors Price by Application (2027-2032) & (USD/ml) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. PD-1 and PD-L1 Inhibitors Distributors List Table 125. PD-1 and PD-L1 Inhibitors Customers List Table 126. PD-1 and PD-L1 Inhibitors Industry Trends Table 127. PD-1 and PD-L1 Inhibitors Industry Drivers Table 128. PD-1 and PD-L1 Inhibitors Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. PD-1 and PD-L1 Inhibitors Product Image Figure 5. Global PD-1 and PD-L1 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global PD-1 and PD-L1 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global PD-1 and PD-L1 Inhibitors Sales (2021-2032) & (L) Figure 8. Global PD-1 and PD-L1 Inhibitors Average Price (USD/ml) & (2021-2032) Figure 9. PD-1 Inhibitors Product Image Figure 10. PD-L1 Inhibitors Product Image Figure 11. Solid Tumors Product Image Figure 12. Blood-related Tumors Product Image Figure 13. Global PD-1 and PD-L1 Inhibitors Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global PD-1 and PD-L1 Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global PD-1 and PD-L1 Inhibitors Sales by Region in 2025 Figure 19. Global PD-1 and PD-L1 Inhibitors Revenue by Region in 2025 Figure 20. North America PD-1 and PD-L1 Inhibitors Market Size by Country in 2025 Figure 21. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 22. North America PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2021-2032) Figure 23. United States PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe PD-1 and PD-L1 Inhibitors Market Size by Country in 2025 Figure 27. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 28. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2021-2032) Figure 29. Germany PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Country in 2025 Figure 40. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2021-2032) Figure 42. China PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America PD-1 and PD-L1 Inhibitors Market Size by Country in 2025 Figure 51. South America PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 52. South America PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2021-2032) Figure 53. Brazil PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country in 2025 Figure 57. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Country (2021-2032) Figure 59. Egypt PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries PD-1 and PD-L1 Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032) Figure 65. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032) Figure 66. Global PD-1 and PD-L1 Inhibitors Price (USD/ml) by Type (2021-2032) Figure 67. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032) Figure 68. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032) Figure 69. Global PD-1 and PD-L1 Inhibitors Price (USD/ml) by Application (2021-2032) Figure 70. PD-1 and PD-L1 Inhibitors Value Chain Figure 71. PD-1 and PD-L1 Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Solid Tumors
  • Blood-related Tumors
Companies covered
  • Merck
  • Bristol-Myers Squibb
  • Roche
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences
  • Merck KGaA

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global PD-1 and PD-L1 Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global PD-1 and PD-L1 Inhibitors Sales (2021-2032)
  5. 2.2.3 Global PD-1 and PD-L1 Inhibitors Market Average Price (2021-2032)
  6. 2.3 PD-1 and PD-L1 Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 PD-1 Inhibitors
  9. 2.3.3 PD-L1 Inhibitors
  10. 2.4 PD-1 and PD-L1 Inhibitors by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Solid Tumors
  13. 2.4.3 Blood-related Tumors
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global PD-1 and PD-L1 Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global PD-1 and PD-L1 Inhibitors Sales (L) of Manufacturers (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global PD-1 and PD-L1 Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of PD-1 and PD-L1 Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of PD-1 and PD-L1 Inhibitors, Established Date
  9. 3.9 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Merck
  2. 4.1.1 Merck Company Information
  3. 4.1.2 Merck Business Overview
  4. 4.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
  6. 4.1.5 Merck Recent Developments
  7. 4.2 Bristol-Myers Squibb
  8. 4.2.1 Bristol-Myers Squibb Company Information
  9. 4.2.2 Bristol-Myers Squibb Business Overview
  10. 4.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
  12. 4.2.5 Bristol-Myers Squibb Recent Developments
  13. 4.3 Roche
  14. 4.3.1 Roche Company Information
  15. 4.3.2 Roche Business Overview
  16. 4.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
  18. 4.3.5 Roche Recent Developments
  19. 4.4 AstraZeneca
  20. 4.4.1 AstraZeneca Company Information
  21. 4.4.2 AstraZeneca Business Overview
  22. 4.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
  24. 4.4.5 AstraZeneca Recent Developments
  25. 4.5 Ono Pharmaceutical
  26. 4.5.1 Ono Pharmaceutical Company Information
  27. 4.5.2 Ono Pharmaceutical Business Overview
  28. 4.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
  30. 4.5.5 Ono Pharmaceutical Recent Developments
  31. 4.6 Regeneron
  32. 4.6.1 Regeneron Company Information
  33. 4.6.2 Regeneron Business Overview
  34. 4.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
  36. 4.6.5 Regeneron Recent Developments
  37. 4.7 Innovent
  38. 4.7.1 Innovent Company Information
  39. 4.7.2 Innovent Business Overview
  40. 4.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
  42. 4.7.5 Innovent Recent Developments
  43. 4.8 Hengrui Medicine
  44. 4.8.1 Hengrui Medicine Company Information
  45. 4.8.2 Hengrui Medicine Business Overview
  46. 4.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
  48. 4.8.5 Hengrui Medicine Recent Developments
  49. 4.9 Junshi Biosciences
  50. 4.9.1 Junshi Biosciences Company Information
  51. 4.9.2 Junshi Biosciences Business Overview
  52. 4.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
  54. 4.9.5 Junshi Biosciences Recent Developments
  55. 4.10 Merck KGaA
  56. 4.10.1 Merck KGaA Company Information
  57. 4.10.2 Merck KGaA Business Overview
  58. 4.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
  60. 4.10.5 Merck KGaA Recent Developments
5 Global PD-1 and PD-L1 Inhibitors Market Scenario by Region
  1. 5.1 Global PD-1 and PD-L1 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America PD-1 and PD-L1 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America PD-1 and PD-L1 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032) & (L)
  3. 6.1.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032) & (L)
  3. 7.1.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
  2. 8.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 PD-1 and PD-L1 Inhibitors Production Mode & Process
  5. 8.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 PD-1 and PD-L1 Inhibitors Distributors
  8. 8.2.3 PD-1 and PD-L1 Inhibitors Customers
9 Global PD-1 and PD-L1 Inhibitors Analyzing Market Dynamics
  1. 9.1 PD-1 and PD-L1 Inhibitors Industry Trends
  2. 9.2 PD-1 and PD-L1 Inhibitors Industry Drivers
  3. 9.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
  4. 9.4 PD-1 and PD-L1 Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst